PL02.15 Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+ NSCLC

作者：A.E. Drilon, B.C. Cho, W. Marston Linehan, B.J. Solomon, Chih‐Feng Lin, A.J. de Langen, E. Felip, Joel W. Neal, Stephen V. Liu, Ross A. Soo, Steven Kao, Juergen Wolf, Geoffrey Liu, C.S. Baik, Christophe Dooms, M. Nagasaka, Anthonie J. van der Wekken, D. Ross Camidge, T. Yoshida, Chih‐Feng Lin, G.-C. Chang, M.-J. Ahn, J.R. Bauman, S. Gadgeel, Antonio Calles, E. Pons-Tostivint, D.S.W. Tan, Michael E. Johnson, C. Bennati, Gianluca Spitaleri, S. Waqar, S. Popat, H. Hayashi, D. Haggstrom, Manoj Samant, Jiayu Shen, Vipul Upadhyay, B. Besse · 发表于：Journal of Thoracic Oncology · 年份：2025 · DOI：10.1016/j.jtho.2025.09.018 · 被引用次数：5 · 研究领域：Chronic Myeloid Leukemia Treatments、PI3K/AKT/mTOR signaling in cancer、Lung Cancer Treatments and Mutations